A significant advancement in skin cancer treatment has arrived. The US FDA has approved cemiplimab, known as Libtayo, to help ...
Expanding the industry’s most comprehensive portfolio of AI applicationsPHILADELPHIA and PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Proscia®, a pathology AI company, will add AI biomarker detection for ...
In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance ...
Spatial biology technologies reveal new dimensions for understanding cellular interactions in their native environment.
Among patients with high-risk cutaneous squamous cell carcinoma (CSCC), postsurgical treatment with Libtayo (cemiplimab-rwlc) has been found to be associated with a similar rate of second primary ...
Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved ...
Many of the signs of perimenopause can also be symptoms of other conditions, and some of these get increasingly dangerous if ...
Philip C. Almond does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...
The threat of a government shutdown looms over Washington this week, as President Donald Trump was set to meet with key congressional leaders at the White House on Monday, Sept. 29, less than 48 hours ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback